[1] [1] SHORT N J, RYTTING M E, CORTES J E. Acute myeloid leukaemia ［J］.?The Lancet, 2018, 392(10147): 593-606.

[2] [2] ADèS L, ITZYKSON R, FENAUX P. Myelodysplastic syndromes ［J］.?The Lancet, 2014, 383(9936): 2239-2252.

[3] [3] MA L, WANG J, ZHANG Y, et al. BRD4 PROTAC degrader MZ1 exerts anti-cancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes ［J］.?Cancer Biology & Therapy, 2022, 23(1): 1-15.

[4] [4] ARBER D A. The 2016 WHO classification of acute myeloid leukemia: what the practicing clinician needs to know ［J］.?Seminars in Hematology, 2019, 56(2): 90-95.

[5] [5] TIAN C, LI Y Y, HU D Z. Advances of targeting therapy in acute myeloid leukemia ［J］. Journal of Experimental Hematology, 2018, 26(4): 1253-1256.

[6] [6] ZOU X, QIU G, CHEN C, et al. Expression pattern and subcellular localization of five splice isoforms of human PXK ［J］.?International Journal of Molecular Medicine, 2005, 16(4): 701-707.

[7] [7] PAUNOLA E, MATTILA P K, LAPPALAINEN P. WH2 domain: a small, versatile adapter for actin monomers ［J］.?FEBS Letters, 2002, 513(1): 92-97.

[8] [8] TAKEUCHI H, TAKEUCHI T, GAO J, et al. Characterization of PXK as a protein involved in epidermal growth factor receptor trafficking ［J］.?Molecular and Cellular Biology, 2010, 30(7): 1689-1702.

[9] [9] PEDERSEN N M, RAIBORG C, BRECH A, et al. The PtdIns3P-binding protein Phafin 2 mediates epidermal growth factor receptor degradation by promoting endosome fusion ［J］. Traffic, 2012, 13(11): 1547-1563.

[10] [10] LI M, ZHAO H. Bioinformatics analysis of the expression and clinical significance of the?NUP210?gene in acute myeloid leukaemia ［J］.?International Journal of Hematology, 2022, 27(1): 456-462.

[11] [11] GU Y, CHU M Q, XU Z J, et al. Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation ［J］.?BMC Medical Genomics, 2022, 15(1): 38.

[13] [13] XIE Q, TANG Z, LIANG X, et al. An immune-related gene prognostic index for acute myeloid leukemia associated with regulatory T cells infiltration ［J］.?International Journal of Hematology, 2022, 27(1): 1088-1100.

[16] [16] NIE L, ZHANG Y, YOU Y, et al. The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients ［J］.?International Journal of Hematology, 2022, 27(1): 840-848.

[18] [18] EVANGELISTA J E, XIE Z, MARINO G B, et al. Enrichr-KG: bridging enrichment analysis across multiple libraries ［J］. Nucleic Acids Research, 2023, 51(W1): W168-W179.

[19] [19] SHALLIS R M, WANG R, DAVIDOFF A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges ［J］.?Blood Reviews, 2019, 36: 70-87.

[20] [20] ENGQVIST-GOLDSTEIN A E, DRUBIN D G. Actin assembly and endocytosis: from yeast to mammals ［J］.?Annual Review of Cell and Developmental Biology, 2003, 19: 287-332.

[22] [22] MARTIN J E, ASSASSI S, DIAZ-GALLO L M, et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci ［J］.?Human Molecular Genetics, 2013, 22(19): 4021-4029.

[23] [23] FERRERO H, CORACHáN A, AGUILAR A, et al. Single-cell RNA sequencing of oocytes from ovarian endometriosis patients reveals a differential transcriptomic profile associated with lower quality ［J］.?Human Reproduction, 2019, 34(7): 1302-1312.

[24] [24] JIN J, CHOU C, LIMA M, et al. Systemic sclerosis is a complex disease associated mainly with immune regulatory and inflammatory genes ［J］.?Open Rheumatology Journal, 2014, 8: 29-42.

[26] [26] NEPSTAD I, HATFIELD K J, GRONNINGSAETER I S, et al. The PI3K-AKT-mTOR signaling pathway in human acute myeloid leukemia (AML) cells ［J］.?International Journal of Molecular Sciences, 2020, 21(8): 2907.

[27] [27] DOS SANTOS C, RECHER C, DEMUR C, et al. The PI3K/AKT/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia ［J］.?Bulletin Du Cancer, 2006, 93(5): 445-447.

[28] [28] LIU Y Q, SHEN J Z, YIN Y, et al. The effects and regulatory mechanism of targeting CXC chemokine receptor 1/2 combined with Ara-C on the malignant biological behaviors of U937 cells of acute myeloid leukemia ［J］.?Journal of Experimental Hematology, 2023, 31(2): 364-376.

[29] [29] ANBAZHAGAN K, RABBIND SINGH A, ISABELLE P, et al. Human pre-B cell receptor signal transduction: evidence for distinct roles of PI3kinase and MAP-kinase signalling pathways ［J］.?Immunity, Inflammation and?Disease, 2013, 1(1): 26-36.

[30] [30] GOURH P, AGARWAL S K, MARTIN E, et al. Association of the C8 orf13-BLK region with systemic sclerosis in North-American and European populations ［J］.?Journal?of Autoimmunity, 2010, 34(2): 155-162.

[31] [31] HUANG H, HUANG S C, HUA D J, et al. Interaction analysis between BLK rs13277113 polymorphism and BANK1 rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745 polymorphism in determining susceptibility to rheumatoid arthritis ［J］.?Autoimmunity, 2017, 50(7): 403-408.

[32] [32] BAI B, WANG T, ZHANG X, et al. PTPN22 activates the PI3K pathway via 14-3-3τ in T cells ［J］. FEBS?Journal, 2023, 290(18): 4562-4576.

[33] [33] BAGHBANI E, BARADARAN B, PAK F, et al. Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways ［J］.?Biomed Pharmacother, 2017, 86: 41-47.

[34] [34] EID R, HAMMAD A, ABDELSALAM M, et al. Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children ［J］.?Lupus Science & Medicine, 2021, 30(9): 1449-1458.

[35] [35] BUDLEWSKI T, SARNIK J, GALITA G, et al. SNP in?PTPN22,?PADI4,?and?STAT4?but Not?TRAF1?and?CD40?increase the risk of rheumatoid arthritis in polish population ［J］.?International Journal of Molecular Sciences, 2023, 24(8): 7586.Medical Journal, 2022, 33(24): 3129-3135.

[36] [36] NEPSTAD I, HATFIELD K J, GRONNINGSAETER I S, et al.The PI3K-AKT-mTOR signaling pathway in human acute myeloidleukemia (AML) cells［ J］. International Journal of Molecular Sciences,2020, 21(8): 2907.

[37] [37] DOS SANTOS C, RECHER C, DEMUR C, et al. The PI3K/AKT/mTOR pathway: a new therapeutic target in the treatment of acutemyeloid leukemia［ J］. Bulletin Du Cancer, 2006, 93(5): 445-447.

[38] [38] LIU Y Q, SHEN J Z, YIN Y, et al. The effects and regulatorymechanism of targeting CXC chemokine receptor 1/2 combinedwith Ara-C on the malignant biological behaviors of U937 cells ofacute myeloid leukemia［ J］. Journal of Experimental Hematology,2023, 31(2): 364-376.

[39] [39] ANBAZHAGAN K, RABBIND SINGH A, ISABELLE P, etal. Human pre-B cell receptor signal transduction: evidence fordistinct roles of PI3kinase and MAP-kinase signalling pathways［J］. Immunity, Inflammation and Disease, 2013, 1(1): 26-36.

[40] [40] GOURH P, AGARWAL S K, MARTIN E, et al. Association of theC8 orf13-BLK region with systemic sclerosis in North-Americanand European populations［ J］. Journal of Autoimmunity, 2010,34(2): 155-162.

[41] [41] HUANG H, HUANG S C, HUA D J, et al. Interaction analysisbetween BLK rs13277113 polymorphism and BANK1rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745polymorphism in determining susceptibility to rheumatoid arthritis［J］. Autoimmunity, 2017, 50(7): 403-408.

[42] [42] BAI B, WANG T, ZHANG X, et al. PTPN22 activates the PI3Kpathway via 14-3-3τ in T cells［ J］. FEBS Journal, 2023, 290(18):4562-4576.

[43] [43] BAGHBANI E, BARADARAN B, PAK F, et al. Suppression ofprotein tyrosine phosphatase PTPN22 gene induces apoptosis inT-cell leukemia cell line (Jurkat) through the AKT and ERK pathways［ J］. Biomed Pharmacother, 2017, 86: 41-47.

[44] [44] EID R, HAMMAD A, ABDELSALAM M, et al. Tumor necrosisfactor receptor II and PTPN22 genes polymorphisms and the riskof systemic lupus erythematosus in Egyptian children［ J］. LupusScience & Medicine, 2021, 30(9): 1449-1458.

[45] [45] BUDLEWSKI T, SARNIK J, GALITA G, et al. SNP in PTPN22,PADI4, and STAT4 but Not TRAF1 and CD40 increase the risk ofrheumatoid arthritis in polish population［ J］. International Journalof Molecular Sciences, 2023, 24(8): 7586.